Imricor Medical Systems Announces License Agreement with Sorin Group

- Focused on Developing MRI Conditional Leads for Cardiac Rhythm Management Products

MINNEAPOLIS, Oct. 9, 2014 /PRNewswire/ -- Imricor Medical Systems, Inc. today announced that it has entered into a license agreement with Sorin Group to develop magnetic resonance imaging (MRI) compatible leads for use with Sorin implantable cardiac rhythm management devices.

Logo - http://photos.prnewswire.com/prnh/20141006/150501

"Imricor has unique knowledge and extensive expertise in the field of MRI compatible technology for implanted medical devices. By means of this agreement, we are working together to develop cardiac rhythm management products that can be used in MRI environments," said Stefano Di Lullo, President, Cardiac Rhythm Management Business Unit, Sorin Group.

"We realize that many patients will benefit from the availability of MR Conditional implanted devices, and Imricor's novel intellectual property can be applied to many of these devices. We look forward to working with Sorin Group to design MR Conditional solutions for their cardiac rhythm management products that outperform anything currently on the market," said Steve Wedan, Imricor's President and Chief Executive Officer.

About Imricor Medical Systems

Imricor Medical Systems is a privately held company that specializes in developing devices and systems that are compatible with magnetic resonance imaging (MRI). Its unique MR-enabled interventional products are designed to provide doctors the ability to perform interventional procedures while taking advantage of the superior soft tissue imaging capabilities of MRI. Imricor is the world leader in the development of MR-enabled devices for electrophysiology applications. Imricor also licenses its technology to help make implanted medical devices compatible with MRI.

For more information, please visit www.imricor.com.

About Sorin Group

Sorin Group is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With over 3,500 employees worldwide, Sorin Group focuses on two major therapeutic areas: Cardiac Surgery and Cardiac Rhythm Management. Every year, over one million patients are treated with Sorin Group devices in more than 100 countries.

For more information, please visit www.sorin.com.

Contact Information
Jodi Lloyd, Communications Manager, Imricor Medical Systems, Inc.
400 Gateway Blvd. Burnsville, MN 55337
Phone: +1 952.818.8417; e-mail: info@imricor.com

Gabriele Mazzoletti, Director Corporate Communications,Sorin Group,
Phone: +39 02 69969785; Mobile: +39 348 9792201; e-mail: corporate.communications@sorin.com